Yashoda Hospitals, Hyderabad saves five-year-old with timely kidney surgery
Approximately five kg tumor was removed in the eight-hour long complicated surgery
Approximately five kg tumor was removed in the eight-hour long complicated surgery
The event was organized jointly by Oncology Forum and Fortis Cancer Institute, Delhi NCR
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
The company has has 10 existing labs in India
The funds will be used to scale up existing operations and launch new products
CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
Suchirayu owns a state-of-the-art multi-speciality hospital in Hubli with an operational capacity of 110 beds and a potential to scale up to 250 beds
ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
 
        Subscribe To Our Newsletter & Stay Updated